Study of cardiovascular disease biomarkers among tobacco consumers, part 1: biomarkers of exposure

References

• Adhikari B, Kahende J, Malarcher A, et al. (2008). Smoking-attributable mortality, years of potential life lost, and productivity losses – United States, 2000–2004. MMWR 57:1226–8
   PubMedGoogle Scholar
• Benowitz, NL. (2003). Cigarette smoking and cardiovascular disease: pathophysiology and implications for treatment. Prog Cardiovasc Dis 46:91–111
   PubMed Web of Science ®Google Scholar
• Byrd GD, Ogden MW. (2003). Liquid chromatographic/tandem mass spectrometric method for the determination of the tobacco-specific nitrosamine metabolite NNAL in smokers’ urine. J Mass Spectrom 38:98–107
   PubMed Web of Science ®Google Scholar
• Calapai G, Caputi AP, Mannucci C, et al. (2009). A cross-sectional investigation of biomarkers of risk after a decade of smoking. Inhal Toxicol 21:1138–43
   PubMed Web of Science ®Google Scholar
• Federal Trade Commission (FTC). (2008). FTC rescinds guidance from 1966 on statements concerning tar and nicotine yields. Available from: http://www.ftc.gov/opa/2008/11/cigarettetesting.shtm. [Last accessed: 7 Nov 2012]
   Google Scholar
• Food and Drug Administration (FDA). (2012). Guidance for industry: reporting harmful and potentially harmful constituents in tobacco products and tobacco smoke under Section 904(a)(3) of the Federal Food, Drug, and Cosmetic Act. Draft guidance. Available from: http://www.fda.gov/downloads/TobaccoProducts/GuidanceComplianceRegulatoryInformation/UCM297828.pdf [Last accessed: 25 Mar 2014]
   Google Scholar
• Gillespie CD, Wigington C, Hong Y. (2013). Coronary heart disease and stroke deaths—United States, 2009. MMWR 62:157–60
   PubMedGoogle Scholar
• Gregg EQ, Minet E, McEwan M. (2013). Urinary biomarkers of smokers' exposure to tobacco smoke constituents in tobacco products assessment: a fit for purpose approach. Biomarkers 18:467–86
   PubMed Web of Science ®Google Scholar
• Hansson J, Galanti MR, Hergens MP, et al. (2012). Use of snus and acute myocardial infarction: pooled analysis of eight prospective observational studies. Eur J Epidemiol 27:771–9
   PubMed Web of Science ®Google Scholar
• Hansson J, Galanti MR, Hergens MP, et al. (2014). Snus (Swedish smokeless tobacco) use and risk of stroke: pooled analyses of incidence and survival. J Int Med 276:87–95
   PubMed Web of Science ®Google Scholar
• Hatsukami DK, Benowitz NL, Rennard SI, et al. (2006). Biomarkers to assess the utility of potential reduced exposure tobacco products. Nicotine Tob Res 8:600–22
   PubMed Web of Science ®Google Scholar
• Heavner DL, Morgan WT, Sears SB, et al. (2006). Effect of creatinine and specific gravity normalization techniques on xenobiotic biomarkers in smokers’ spot and 24-h urines. J Pharm Biomed Anal 40:928–42
   PubMed Web of Science ®Google Scholar
• Hecht SS, Carmella SG, Edmonds A, et al. (2008). Exposure to nicotine and a tobacco-specific carcinogen increase with duration of use of smokeless tobacco. Tob Control 17:128–31
   PubMed Web of Science ®Google Scholar
• Hecht SS, Carmella SG, Murphy SE, et al. (2007). Similar exposure to a tobacco-specific carcinogen in smokeless tobacco users and cigarette smokers. Cancer Epidemiol Biomarkers Prev 16:1567–72
   PubMed Web of Science ®Google Scholar
• Henley SJ, Connell CJ, Richter P, et al. (2007). Tobacco-related disease mortality among men who switched from cigarettes to spit tobacco. Tob Control 16:22–8
   PubMed Web of Science ®Google Scholar
• Henley SJ, Thun MJ, Connell C, Calle EE. (2005). Two large prospective studies of mortality among men who use snuff or chewing tobacco (United States). Cancer Causes Control 16:347–58
   PubMed Web of Science ®Google Scholar
• Heudorf U, Angerer J. (2001). Urinary monohydroxylated phenanthrenes and hydroxypyrene – the effects of smoking habits and changes induced by smoking on monooxygenase-mediated metabolism. Int Arch Occup Environ Health 74:177–83
   PubMed Web of Science ®Google Scholar
• Institute of Medicine (IOM). (2011). Scientific standards for studies on modified risk tobacco products. Washington, DC: The National Academies Press
   Google Scholar
• International Agency for Research on Cancer (IARC). (2007). Smokeless tobacco and some tobacco-specific N-nitrosamines. IARC monographs on the evaluation of carcinogenic risks to humans, volume 89. Lyon, France: World Health Organization
   Google Scholar
• Jilma B, Dirnberger E, Löscher I, et al. (1997). Menstrual cycle-associated changes in blood levels of interleukin-6, alpha1 acid glycoprotein, and C-reactive protein. J Lab Clin Med 130:69–75
   PubMedGoogle Scholar
• Lee PN, Hamling J. (2009). Systematic review of the relation between smokeless tobacco and cancer in Europe and North America. BMC Med 7:36
   PubMed Web of Science ®Google Scholar
• Lowe FJ, Gregg EO, McEwan M. (2009). Evaluation of biomarkers of exposure and potential harm in smokers, former smokers and never-smokers. Clin Chem Lab Med 47:311–20
   PubMed Web of Science ®Google Scholar
• Marano KM, Kathman SJ, Jones BA, et al. (2015). Study of cardiovascular disease biomarkers among tobacco consumers, part 3: evaluation and comparison with the US National Health and Nutrition Examination Survey. Inhal Toxicol. (in press)
   Google Scholar
• Meger M, Meger-Kossien I, Schuler-Metz A, et al. (2002). Simultaneous determination of nicotine and eight nicotine metabolites in urine of smokers using liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 778:251–61
   PubMed Web of Science ®Google Scholar
• Messner B, Bernhard D. (2014). Smoking and cardiovascular disease mechanisms of endothelial dysfunction and early atherogenesis. Arterioscler Thromb Vasc Biol 34:509–15
   PubMed Web of Science ®Google Scholar
• Nan HM, Kim H, Lim HS, et al. (2001). Effects of occupation, lifestyle and genetic polymorphisms of CYP1A1, CYP2E1, GSTM1 and GSTT1 on urinary 1-hydroxypyrene and 2-naphthol concentrations. Carcinogenesis 22:787–93
   PubMed Web of Science ®Google Scholar
• Naufal ZS, Marano KM, Kathman SJ, Wilson CL. (2011). Differential exposure biomarker levels among cigarette smokers and smokeless tobacco consumers in the National Health and Nutrition Examination Survey 1999-2008. Biomarkers 16:222–35
   PubMed Web of Science ®Google Scholar
• Nordskog BK, Brown BG, Marano KM, et al. (2015). Study of cardiovascular disease biomarkers among tobacco consumers, part 2: biomarkers of biological effect. Inhal Toxicol. (in press)
   Google Scholar
• Nutt DJ, Phillips LD, Balfour D, et al. (2014). Estimating the harms of nicotine-containing products using the MCDA approach. Eur Addict Res 20:218–25
   PubMed Web of Science ®Google Scholar
• Piano MR, Benowitz NL, Fitzgerald GA, et al. (2010). Impact of smokeless tobacco products on cardiovascular disease: implications for policy, prevention, and treatment: a policy statement from the American Heart Association. Circulation 122:1520–44
   PubMed Web of Science ®Google Scholar
• Roethig HJ, Munjal S, Feng S, et al. (2009). Population estimates for biomarkers of exposure to cigarette smoke in adult U.S. cigarette smokers. Nicotine Tob Res 11:1216–25
   PubMed Web of Science ®Google Scholar
• Scherer G. (2005). Biomonitoring of inhaled complex mixtures – ambient air, diesel exhaust and cigarette smoke. Exp Toxicol Pathol 57(Suppl. 1):75–110
   PubMed Web of Science ®Google Scholar
• Stepanov I, Hecht SS. (2005). Tobacco-specific nitrosamines and their pyridine-N-glucuronides in the urine of smokers and smokeless tobacco users. Cancer Epidemiol Biomarkers Prev 14:885–91
   PubMed Web of Science ®Google Scholar
• Stratton K, Shetty P, Wallace R, Bondurant S. (2001). Clearing the smoke: the science base for tobacco harm reduction—executive summary. Tob Control 10:189–95
   PubMed Web of Science ®Google Scholar
• Thun MJ, Apicella LF, Henley SJ. (2000). Smoking vs other risk factors as the cause of smoking-attributable deaths: confounding in the courtroom. J Am Med Assoc 284:706–12
   PubMed Web of Science ®Google Scholar
• US Department of Health and Human Services. (USDHHS). (2004). The health consequences of smoking: a report of the Surgeon General. Atlanta, GA: Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health
   Google Scholar
• US Department of Health and Human Services. (USDHHS). (2010). How tobacco smoke causes disease: the biology and behavioral basis for smoking-attributable disease: a report of the Surgeon General. Atlanta, GA: Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health
   Google Scholar
• Vesper HW, Caudill SP, Osterloh JD, et al. (2010). Exposure of the U.S. population to acrylamide in the National Health and Nutrition Examination Survey 2003–2004. Environ Health Perspect 118:278–83
   PubMed Web of Science ®Google Scholar
• World Health Organization (WHO). (2013). Cardiovascular diseases (CVDs), Fact Sheet No. 317. Available from: http://www.who.int/mediacentre/factsheets/fs317/en/. [Last accessed: 27 Mar 2014]
   Google Scholar
• Zeller M, Hatsukami D, Strategic Dialogue on Tobacco Harm Reduction Group. (2009). The Strategic Dialogue on Tobacco Harm Reduction: a vision and blueprint for action in the US. Tob Control 18:324–32
   PubMed Web of Science ®Google Scholar